Charles River Laboratories International, Inc. (CRL)
NYSE · Healthcare
Charles River Laboratories International, Inc. Shareholder Equity 2008–2025
Charles River Laboratories International, Inc. annual shareholder equity history from 2009 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Charles River Laboratories International, Inc. shareholder equity as of December 27, 2025: 3.16B, a 8.58% decrease year-over-year.
- Charles River Laboratories International, Inc. shareholder equity for 2025 were 3.16B, a 8.58% decrease from 2024.
- Charles River Laboratories International, Inc. shareholder equity for 2024 were 3.46B, a 3.76% decrease from 2023.
- Charles River Laboratories International, Inc. shareholder equity for 2023 were 3.60B, a 20.85% increase from 2022.
- Charles River Laboratories International, Inc. shareholder equity for 2022 were 2.98B.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Charles River Laboratories International, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $3,165 |
| 2024 | $3,462 |
| 2023 | $3,597 |
| 2022 | $2,976 |
| 2021 | $2,535 |
| 2020 | $2,115 |
| 2019 | $1,635 |
| 2018 | $1,317 |
| 2017 | $1,045 |
| 2016 | $837 |
| 2015 | $733 |
| 2014 | $672 |
| 2013 | $641 |
| 2012 | $601 |
| 2011 | $526 |
Charles River Laboratories International, Inc. Shareholder Equity — FAQ
Charles River Laboratories International, Inc. (CRL) shareholder equity over the last 18 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CRL's shareholder equity history?
The chart and table above show Charles River Laboratories International, Inc.'s shareholder equity by year and by quarter, including the growth rate.